Genome Life Sciences

Genome Life Sciences (GLS) is a DSIR-recognized Genomics & Biomarker discovery company and a prominent provider of start-to-finish Next-Generation Sequencing and data analysis services, custom database development, contract research and bioinformatics consulting. The company provides life science databases of unique content developed with data mining algorithms along with their interactive and dynamic user interfaces. GLS helps customers worldwide meet the bioinformatics challenges with its powerful tools and technologies. Our clients include academia, federal and private industries from USA and Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ENVIRAL TECH ANNOUNCES THE AVAILABILITY OF ITS SARS-COV-2 (COVID-19) SURFACE CHECK AND AIR CHECK TEST KITS

Enviral Tech | August 07, 2020

news image

Enviral Tech, a biotechnology company that provides molecular hygiene testing for the management of pandemic and post-pandemic facility safety assurance, is pleased to announce the availability of its SARS-CoV-2 (COVID-19) Surface Check and Air Check Test Kits. Available throughout the United States, the kits can be used on any surface or in any environment for early detection of the COVID-19 virus to ensure the health of communities, prevent new infection, and restore consumer confidence....

Read More

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

news image

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More

MEDTECH

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

news image

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

news image

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More
news image

ENVIRAL TECH ANNOUNCES THE AVAILABILITY OF ITS SARS-COV-2 (COVID-19) SURFACE CHECK AND AIR CHECK TEST KITS

Enviral Tech | August 07, 2020

Enviral Tech, a biotechnology company that provides molecular hygiene testing for the management of pandemic and post-pandemic facility safety assurance, is pleased to announce the availability of its SARS-CoV-2 (COVID-19) Surface Check and Air Check Test Kits. Available throughout the United States, the kits can be used on any surface or in any environment for early detection of the COVID-19 virus to ensure the health of communities, prevent new infection, and restore consumer confidence....

Read More
news image

RESEARCH

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More
news image

MEDTECH

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More
news image

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us